Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers
Year: 2015
Type: article
Abstract: BACKGROUND: Chemoresistance is a major challenge in cancer treatment. miR-506 is a potent inhibitor of the epithelial-to-mesenchymal transition (EMT), which is also associated with chemoresistance. We characterized the role of miR-506 in chemotherapy response in high-grade serous ovarian cancers. METHODS: We used Kaplan-Meier and log-rank methods to analyze the relationship between miR-506 and progression-free and overall survival in The Cancer Genome Atlas (TCGA) (n = 468) and Bagnoli (n = 130) datasets, in vitro experiments to study whether miR-506 is associated with homologous recombination, and response to chemotherapy agents. We used an orthotopic ovarian cancer mouse model (n = 10 per group) to test the effect of miR-506 on cisplatin and PARP inhibitor sensitivity. All statistical tests were two-sided. RESULTS: MiR-506 was associated with better response to therapy and longer progression-free and overall survival in two independent epithelial ovarian cancer patient cohorts (PFS: high vs low miR-506 expression; Bagnoli: hazard ratio [HR] = 3.06, 95% confidence interval [CI] = 1.90 to 4.70, P < .0001; TCGA: HR = 1.49, 95% CI = 1.00 to 2.25, P = 0.04). MiR-506 sensitized cells to DNA damage through directly targeting the double-strand DNA damage repair gene RAD51. Systemic delivery of miR-506 in 8-12 week old female athymic nude mice statistically significantly augmented the cisplatin and olaparib response (mean tumor weight ± SD, control miRNA plus cisplatin vs miR-506 plus cisplatin: 0.36±0.05g vs 0.07±0.02g, P < .001; control miRNA plus olaparib vs miR-506 plus olaparib: 0.32±0.13g vs 0.05±0.02g, P = .045, respectively), thus recapitulating the clinical observation. CONCLUSIONS: MiR-506 is a robust clinical marker for chemotherapy response and survival in serous ovarian cancers and has important therapeutic value in sensitizing cancer cells to chemotherapy.
DOI: 10.1093/jnci/djv108
Authors: Guoyan Liu, Da Yang, Rajesha Rupaimoole, Chad V. Pecot, Yan Sun, Lingegowda S. Mangala, Xia Li, Ping Ji, David Cogdell, Limei Hu, Yingmei Wang, Cristian Rodriguez-Aguayo, Gabriel Lopez-Berestein, Ilya Shmulevich, Loris De Cecco, Kexin Chen, Delia Mezzanzanica, Fengxia Xue, Anil K. Sood, Wei Zhang
Institutions: The University of Texas MD Anderson Cancer Center, Tianjin Medical University General Hospital, Tianjin Medical University Cancer Institute and Hospital, Fondazione IRCCS Istituto Nazionale dei Tumori, Tianjin Medical University, Air Force Medical University, Institute for Systems Biology
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
Funders: Ovarian Cancer Research Fund, Elsa U. Pardee Foundation, National Foundation for Cancer Research, Cancer Prevention and Research Institute of Texas, University of Pittsburgh, National Natural Science Foundation of China, Associazione Italiana per la Ricerca sul Cancro, Tianjin Science and Technology Committee, National Institutes of Health, University of Texas MD Anderson Cancer Center, National Cancer Institute, Program for Changjiang Scholars and Innovative Research Team in University
Awards: TGFBI-integrin-FAK信号转导通路在紫杉醇诱导多倍体肿瘤形成和耐药中的作用, G1468253849, G1563648064, MD Anderson Gynecologic SPORE for Uterine Cancers, Texas Center for Cancer Nanomedicine, Research Training in Academic Medical Oncology, G4031895823, G717078306, G788993117, Center for Systems Analysis of the Cancer Regulome, The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer, Cancer Center Support Grant
OpenAlex ID: W1947613625